Market Overview

Citigroup Reiterates Buy Rating, $60 PT on CVS Caremark Corporation

Share:
Related CVS
CVS Health Says Overdose-Reversal Drug Is Now Available Without A Prescription In Texas
Barron's Picks And Pans: Pharmacy-Benefit Managers, Mortgage Insurers And More
Focus On Quality For Long-Term Success (Seeking Alpha)

In a report published Monday, Citigroup reiterated its Buy rating and $60.00 price target on CVS Caremark Corporation (NYSE: CVS).

Citigroup noted, “We expect investors to focus on: 1) WAG/ESRX script retention; 2) the 2013 PBM selling season; 3) PBM streamlining initiatives; 4) opportunities to drive utilization, incl. Maintenance Choice (MC), generics, and healthcare reform; 5) specialty; 6) int'l expansion; and 7) capital allocation. CVS's unique business model continues to gain traction, and we anticipate optimistic 2013 guidance to be provided. CVS is Buy-rated and on Citi's Top Picks Live! list.”

CVS Caremark Corporation closed on Friday at $47.23.

Latest Ratings for CVS

DateFirmActionFromTo
Jun 2016Morgan StanleyDowngradesEqual-weight
May 2016JefferiesMaintainsBuy
May 2016CitigroupMaintainsNeutral

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Reiteration Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!